Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry

被引:52
|
作者
Godoy-Ramirez, K [1 ]
Franck, K
Mahdavifar, S
Andersson, L
Gaines, H
机构
[1] Swedish Inst Infect Dis Control, Dept Immunol & Vaccinol, SE17182 Solna, Sweden
[2] Karolinska Inst, Ctr Microbiol & Tumorbiol, S-10401 Stockholm, Sweden
关键词
intracellular cytokines; flow cytometry; whole blood; PBMC;
D O I
10.1016/j.jim.2004.04.028
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The assessment of cytokine production is an important component of studies of cell-mediated immune responses (CMI) to immunological challenges. In this study, we present a method to enhance the detection of cytokine-producing cells by allowing antigen-specific cells to expand in long-term culture. We investigated the influence of the degree of dilution of whole blood and the duration of the incubation period on whole blood as well as peripheral blood mononuclear cells (PBMCs), cultured in the absence or presence of mitogens, superantigens or specific antigens, for intracellular cytokine production (IFNgamma, TNFalpha, IL-2, IL-4, IL-10 and IL-13) by CD4(+) and CD8(+) T lymphocytes using four-colour flow cytometry. Whole blood was diluted 1/1, 1/2, 115 and 1 /10, and cultured for 6, 24, 48, 72 and 120 h in the presence of antibodies against the co-stimulatory molecules CD28 and CD49d, and, during the last 4 h of culture, in the presence of brefeldin A. Optimum conditions for detection of a high number of IFN-gamma-positive cells were observed after 72 h of culture in blood diluted 1/10. Median frequencies of IFNgamma(+) cells obtained after activation by PMA-ionomycin, PHA or SEA-B were 29.3%, 20.0%and 6.8% for CD4(+) cells, and 67.8%, 20.6% and 6.8% for CD8(+) cells. In blood samples diluted 1/5 or 1/10, and cultured in the presence of cytomegalovirus (CMV) or varicella-zoster virus (VZV), mean peak levels of 2.8% and 1.4% IFNgamma(+)CD4(+) cells were recorded at 120 h. The levels of cells producing cytokines other than IFNgamma were generally much lower and, in the case of IL-4 and IL-13, difficult to distinguish from backgound levels recorded in cultures with medium only. Kinetic studies of cytokine production by PBMCs showed a pattern similar to that of whole blood with peak levels of IFN-gamma-producing cells recorded at 72 h. The increased levels of IFNgamma production after culture for 72 h were due to an expansion of the numbers of cytokine-producing cells responsive to a specific stimulus. Antigen-specific cells are usually present only at low levels in peripheral blood and may not be detected following simple activation for a few hours. To reach a level of detection in such cases, culture of diluted blood for several days is recommended. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 50 条
  • [41] Platelet activation and phosphatidylserine (PS) expression in type II diabetics using whole blood flow cytometry.
    Dwyre, DM
    Janatpour, KA
    MacKenzie, MR
    Cheung, ATW
    Paglieroni, T
    Crocker, V
    Gosselin, R
    Ramanujam, S
    Duong, PL
    Larkin, EC
    BLOOD, 2001, 98 (11) : 44B - 44B
  • [42] Identification of surface molecules associated with physiologic activation of eosinophils - Application of whole-blood flow cytometry to eosinophils
    Mawhorter, SD
    Stephany, DA
    Ottesen, EA
    Nutman, TB
    JOURNAL OF IMMUNOLOGY, 1996, 156 (12): : 4851 - 4858
  • [43] Type 2 diabetes is associated with decreased activation and increased cytokine production by blood lymphocytes: a human flow cytometry study
    Gasparini, D.
    Kavazovic, I.
    Mijolovic, Z.
    Klaric, I.
    Drmic, A. Prunk
    Persic, V.
    Wensveen, F. M.
    Wensveen, T. Turk
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S268 - S269
  • [44] Whole blood flow cytometry measurements of in vivo platelet activation in critically-Ill patients are influenced by variability in blood sampling techniques
    Rondina, Matthew T.
    Grissom, Colin K.
    Men, Shaohua
    Harris, Estelle S.
    Schwertz, Hansjorg
    Zimmerman, Guy A.
    Weyrich, Andrew S.
    THROMBOSIS RESEARCH, 2012, 129 (06) : 729 - 735
  • [45] Advanced Flow Cytometry Using the SYTO-13 Dye for the Assessment of Platelet Reactivity and Maturity in Whole Blood
    Pedersen, Oliver Buchhave
    Pasalic, Leonardo
    Grove, Erik Lerkevang
    Kristensen, Steen Dalby
    Hvas, Anne-Mette
    Nissen, Peter H.
    METHODS AND PROTOCOLS, 2023, 6 (01)
  • [46] Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation
    Tarnow, Inge
    Kristensen, Annemarie T.
    Krogh, Anne K. R.
    Frelinger, Andrew L., III
    Barnard, Marc R.
    Michelson, Alan D.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2008, 123 (3-4) : 345 - 352
  • [47] Effect of a glycoprotein IIb/IIIa inhibitor on platelet activation and aggregation as measured by aggregometry and whole blood flow cytometry.
    Koza, MJ
    Hoppensteadt, DA
    Walenga, JM
    Fareed, J
    Bermes, EW
    Pifarre, R
    CLINICAL CHEMISTRY, 1996, 42 (06) : 411 - 411
  • [48] Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies
    Hanekom, WA
    Hughes, J
    Mavinkurve, M
    Mendillo, M
    Watkins, M
    Gamieldien, H
    Gelderbloem, SJ
    Sidibana, M
    Mansoor, N
    Davids, V
    Murray, RA
    Hawkridge, A
    Haslett, PAJ
    Ress, S
    Hussey, GD
    Kaplan, G
    JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 291 (1-2) : 185 - 195
  • [49] Evaluation of an Easy Flow-Cytometric Assay for Detection of Specific Cell Mediated Immunity in Activated Whole Blood or PBMC from Chickens
    Dalgaard, T.
    Norup, L. R.
    Pleidrup, J.
    Kjaerup, R. M.
    Wattrang, E.
    Juul-Madsen, H. R.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2013, 77 (04) : 294 - 294
  • [50] Single cell network profiling (SCNP) by flow cytometry as a tool to measure potency and selectivity of JAK/STAT inhibitors in PBMC and whole blood discrete cell subsets
    Covey, Todd M.
    Putta, Santosh
    Gulrajani, Michael
    Cohen, Aileen C.
    Cesano, Alessandra
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)